Population Decolonized and Decolonization Regimen
|
|
- Della Allison
- 5 years ago
- Views:
Transcription
1 Appendix Table 1a Characteristics Studies Evaluating a Bundle Including Decolonization and Glycopeptide Prophylaxis as a Means of Preventing Gram-Positive Surgical Site Infections First Author, Year, Location Study Design, Sample Size (n), Reviewed Publication? Study Dates Patient Screened For Number of Nasal S. aureus Carriers Decolonized and Decolonization Regimen Antimicrobial Agents Compared Outcome Definition and Assessment Mupirocin Resistance Gram-positive SSI RR (95% CI) a Jog 2008, Plymouth, UK Walsh 2011, Rochester, NY, Kim 2010, Boston, MA, Sporer 2011, Wheaton, IL, Acebedo 2009, (n=1,462), (n=5,262) (n=12,312) (n=4,873), t (n=1,981), 2004-Sept 2005; 2005-Sept Jan 2007; Period: Feb Jan 2010 Period: July 2006-Sept 2007; 2005-July 2006 Period: July Dec 2008; July 2009 Period: Aug Cardiothoracic PCR PCR group, 19/765 were group, 56/2,496 were group, 1,588/7,019 were and 309/7,019 were group 4.3% were 18% were t stated began 2% nasal until PCR results were known; if PCR was negative, was stopped; if PCR was positive, was continuee; topical triclosan for all received nasal c 1 day, 4 days postoperatively ; 2% nasal BID for 5 days; 2% CHG shower qd for 5 days ; 2% nasal for 5 days ; CHG bathing for all Only Teicoplanin and gentamicin carriers vs. flucloxacillin and gentamicin negative Vancomycin and carriers vs. negative Vancomycin carriers Vancomycin to carriers vs. for negative Vancomycin and Definition established by the English Health Protection Agency; infection control staff assessed SSI CDC definition; assessed by an infection prevention practitioner in consultation with an infectious disease specialist and with a cardiothoracic surgeon CDC definition; assessed by surgeons and infection control staff Purulent drainage from wound, note in medical record from surgeon stated that patient had an SSI SSI within 1 year; definition was not t stated 0.56 (0.23, 1.34) 10/12 randomly selected isolates from control period were susceptible to ; 10/10 randomly selected isolates from intervention period were susceptible to t stated 0.26 (0.13, 0.52) 0.41 b (0.21, 0.80) t stated 0.56 (0.29, 1.09) t stated 0.48 (0.21, 1.07)
2 Cincinnati, OH, Rao 2011, Pittsburgh, PA, t (n=2,181) 2004-Aug 2005; Period: Dec 2005-Dec Oct 2005; 2005-Oct 2007 on CHROM agar group 278/1440 were and 43/1440 were ; nasal c BID for 5 days; CHG qd for 5 days if positive or CHG qd 3 days if negative Only ; nasal c BID 5 days ; CHG qd for 5 days for carriers carriers vs. for negative Vancomycin for carriers or those with history of vs. for negative specified; assessed by infection control staff SSI within 1 year; definition was not specified; did not t stated 0.23 b (0.08, 0.67) Hadley 2010, New York, NY, (n=2,058) v June 2009 group, 351/1,644 were and 58/1,644 were ; 2% nasal for 5 days; CHG shower 1 day before the operation Vancomycin for carriers vs. or clindamycin for negative did not specify who made the assessment t stated 0.76 b (0.08, 7.24) a Some studies provided data on only S. aureus SSIs, not all Gram-positive SSIs; b These studies provided data on only S. aureus SSIs not all Gram-positive SSIs; c Percent not defined te:, quasi-experimental;, methicillin-resistant S. aureus;, methicillin-susceptible S. aureus; qd, daily; BID, two times a day; CHG, chlorhexidine; RR, relative risk; CI, confidence interval; BID, two times a day; PCR, polymerase chain reaction; CDC, Centers for Disease and Prevention; SSI, surgical site infection
3 Appendix Table 1b Characteristics of Studies Evaluating Nasal Decolonization as a Means of Preventing Gram-Positive Surgical Site Infections First Author, Year, Location Study Dates Patient Screened For Number of Nasal S. aureus Carriers Bundled? Study Design, Sample Size (n), Reviewed Publication? Randomized led Trials (RCT) Konvalinka 2006, Toronto, ON, Canada Perl 2002, Iowa City, IA, Segers 2006, Amsterdam, The Bode 2010, Rotterdam, The Double blinded RCT (n=257) Double blinded RCT (n=699) Double blinded RCT (n=954) Doubleblinded RCT (n=505) Mar Mar 2003 Apr Dec 1998 Aug Sept 2005 Oct June 2007 CABG or Valve and PCR 130 in group, 127 in placebo group 430 in group, 439 in placebo group; 6/1021 S. aureus isolates were resistant; 3/6 were from treated with placebo 321/954 were, 2/954 were. difference in colonization in the CHG and placebo groups 505 in - CHG group, 413 in placebo group Decolonized and Decolonization Regimen carriers; 2% nasal BID for 7 days All regardless of colonization; 2% nasal BID for up to 5 days All regardless of CHG QID then QID until nasogastric tube removed carriers; 2% nasal administration varied Yes, oral CHG Yes, CHG soap for S. aureus carriers randomized to Outcome Definition and Assessment Occurrence of 1 of the following within 8 weeks of the operation: the presence of exudate from the wound, the edges of the wound were erythematous beyond a 2 cm margin, the wound culture yielded a pathogen with signs of inflammation, or a physician stated in the medical record that the surgical site was infected as corroborated by one or more of the listed criteria; assessed by surgeon and researcher assessed by infection control staff and a researcher assessed by a researcher assessed by a researcher Mupirocin Resistance Short-term use did not select for resistant S. aureus 6/1021 S. aureus isolates were resistant, 3 of these were from treated with placebo Gram-positive SSI RR (95% CI) a 1.22 (0.34, 4.44) 0.80 b (0.34, 1.91) t stated 0.82 (0.53, 1.28) All strains were susceptible 0.14 b (0.04, 0.49)
4 decolonization to Kalmeijer 2002, Rotterdam, The Doubleblinded RCT (n=614) Observational studies Cimochowski 2001, Wilkes- (n=1,846) Barre, PA, Coskun 2005, Istanbul, Turkey Graf 2009, Hannover, Germany Kluytmans 1996, Dijkzigt, The Martorell 2004, Springfield, MA, Nicholson 2006, Cincinnati, OH, (n= 12,066) (n=308) (n=868) (n=935) (n=2,031) Jan July Oct 1996; Period: Dec 1997-Mar Dec v Sept 2007; 2007-Mar 2008 Period: Aug 1989-Feb 1991; Period: Mar 1991-Aug 1992 Period: ; Period: 9 months of Apr 2003; Period: Apr 2003-Sept 2004 Open Heart Cardiovascular Cardiothoracic CABG Cardiovascular t t (nasal, oral) t 95 in group, 86 in placebo group 126/472 in control group, 26/100 in t stated t stated 16.0% of ; 15.1% of control group t stated 222/1077 in the All regardless of colonization; 2.15% nasal BID; administration varied c 2 preoperative doses, BID for 5 days postoperatively c TID for 3 days Nasal ; did not specify who was decolonized or the dose of c c 1 dose, BID for 5 days postoperatively c for 3 days received 2% nasal 1 dose and BID until culture results were known, if culture was negative, was Yes, and decolonized healthcare workers Yes, CHG throat rinse and antiseptic body scrub, plus 14 item prevention bundle Yes, 1 day CHG bathing researcher utilized a standardized questionnaire to determine whether the wound met the SSI definition Modified CDC criteria; assessed by surgeons and/or infection control staff Did not Did not assessed by a researcher NNIS definitions; assessed by the surgeon and infection control staff CDC HICPAC definition; assessed by infection control staff All strains were susceptible to 1 strain from the intervention group was resistant t stated t stated Mupirocin resistant S. aureus not observed t stated t stated 0.59 b (0.20, 1.79) 0.31 (0.11, 0.82) 0.60 b (0.35, 1.02) 0.41 b (0.19, 0.86) 0.28 (0.11, 0.75) 0.27 b (0.08, 0.97) 0.22 b (0.07, 0.66)
5 Coskun 2004, Istanbul, Turkey Gernaat-van der Sluis 1998, Nijmegen, The Price 2008, Denver, CO, Hacek 2008, Evanston, IL, Sankar 2005, Worcestershire, UK Wilcox 2003, Leeds UK (n=3,249) (n=2,304) Cross sectional analysis (n=88) (n=1,495) (n=396) (n=4,120) 1999-Dec 2000, 2001-Dec 2003 Period: July 1992-July 1994; Period: Aug Jan 1996 Sept Sept 2005 Period: Feb 2003-July 2003; Period: Aug 2003-Feb Oct 2001; Period: Apr 2001-Oct Mar 1999; Period: Apr t t PCR t stated t stated 81/284 were and 5/284 were 223/912 in stopped, if culture was positive, was continued for a total of 14 doses c TID for 3 days c 3 doses carriers; 2% nasal for at least 6 doses ; nasal c BID for 5 days t stated Only carriers in the intervention group; nasal c t 28/74 were in the control period; 49/361 in the intervention period c 1 dose, 4 Yes, axilla and groin for, if positive provided povidone iodine or triclosan; if any site +, admission was delayed until 3 consecutive swabs were negative Yes, triclosan did not did not CDC definition; did not specify who made the assessment assessed by infection control staff and a researcher t defined; did not CDC NNIS criteria; microbiology lab ward liaison surveillance and surgeons t stated t stated Did not assess Tested for high-level resistance but results not stated 0.25 b (0.11, 0.58) 0.60 b (0.24, 1.49) 0.19 b (0.01, 3.86) 0.43 (0.19, 0.94) t stated 0.24 (0.01, 5.78) Low-level resistance was found in 2.3% (2/88) of S. aureus 0.17 b (0.08, 0.33)
6 1999-Mar 2001 times postoperatively isolates during control period, and in 4.2% (6/143) in intervention period (not significant) a Some studies provided data only on S. aureus SSIs, not all Gram-positive SSIs; b These studies provided data on only S. aureus SSIs not all Gram-positive SSIs; c Percent not defined te: RCT, randomized controlled trial;, quasi-experimental; RR, relative risk; CI, confidence interval; CABG, coronary artery bypass surgery, BID, two times a day; TID, three times a day; QID, four times a day;, methicillin-resistant S. aureus;, methicillin-susceptible S. aureus; PCR, polymerase chain reaction; CDC, Centers for Disease and Prevention; NNIS, National socomial Infection Surveillance System; NHSN, National Health Safety Network; HICPAC, Healthcare Infection Practices Advisory Committee; SSI, surgical site infection
7 Appendix Table 1c Characteristics of Studies Evaluating Glycopeptide Prophylaxis as a Means of Preventing Gram-Positive Surgical Site Infections First Author, Year, Study Location Study Design and Sample Size (n), Reviewed Publication? Study Dates Patient Bundle? Antimicrobial Agents Compared Outcome Definition and Assessment Randomized led Trials (RCT) Dhadwal 2007, Middlesex, UK Finkelstein 2002, Haifa, Israel Niederhäuser 1997, Zurich, Switzerland Saginur 2000, Canada Salminen 1999, Helsinki, Finland Vuorisalo 1998, Oulu, Finland Periti 1999, Italy Tyllianakis 2010, Rio-Patras, Greece (Hellas) Double-blinded RCT (n=186), RCT, t blinded (n=886), RCT, t blinded (n=55), Double-blinded RCT (n=3,027), RCT, t blinded (n=200), RCT, t blinded (n=884), Reviewed RCT, Outcome assessment blinded (n=826), RCT, t blinded (n=317), Observational Studies Pear 1998, (n=242), Tucson, AZ, Spelman 2002, Prahran, VIC, AUS Bull 2010, rth Melbourne, VIC, AUS (n=1,114), Retrospective cohort study (n=22,777), t June 2003-May 2004 Jan 1997-Dec 1999 Jan 1991-Jan 1994 t stated After May 1994 CABG CABG or Valve CABG or Valve CABG Oct 1989-July Hip and Knee Standard Care Period: Jan 1995-Dec 1995; Limited Vancomycin 1996-June 1996 Period: Feb 1999-Jan 2000; Period: Feb 2000-Jan 2001 t stated CABG CABG Surgery and Yes, CHG bathing Vancomycin and rifampin and gentamicin vs. cefuroxime Group 1: prolonged ticarcillin/ clavulante and vancomycin and vs. Group 2: Teicoplanin vs. ceftriaxone cefuroxime Teicoplanin vs cefuroxime Vancomycin +/- cefalosporin vs. cephalosporins Vancomycin and rifampin vs. beta-lactams CDC definition evaluated within 90 days; assessed by surgeons, infection control staff CDC definition; assessed by surgeons, infection control staff, and researchers CDC definition, did not the assessment Cellulitis with systemic signs of infection and/or purulent wound discharge within 30 days or 6 months; Deep SSI: drainage required; did not Gram-positive SSI RR (95% CI) a 0.46 (0.15, 1.40) 1.07 (0.69, 1.66) 0.30 (0.01, 7.02) 1.38 (0.99, 1.90) Purulent secretion; assessed by researcher 1.26 (0.29, 5.47) CDC definition; assessed by surgeons and infection control staff Hematoma with bacteriological evidence of infection on aspirate, inflammation or pain with purulent exudate, fever, leukocytosis, severe pain, increased erythrocyte sedimentation rate with leukocytes; did not specify who made Erythema, local pain, tenderness, drainage, possibly radiographic changes, fever/night sweats, dehiscence; did not 0.79 (0.36, 1.73) 1.01 (0.30, 3.48) 0.87 (0.21, 3.59) CDC definition; did not 0.62 (0.14, 2.71) CDC definition; assessed by infection control staff 0.05 b (0.01, 0.20) Definition and assessment not stated 1.29 (0.91, 1.82) Gupta 2011, Retrospective Jan Dec 2009 Surgery Yes, VA Vancomycin +/- CDC NHSN definition; assessed by infection control staff 0.92
8 Boston, MA, Merrer 2006, Paris, France Sewick 2012, Philadelphia, PA, Soriano 2006, Barcelona, Spain cohort study (n=990), Reviewed (n=258), Retrospective cohort study (n=1,828), (n=763), Mar 2004-Feb 2005 Sept 2008-Dec 2010 Cefuroxime 2002-May 2002; Cefuroxime+teicoplanin Period: Jun 2002-May 2003 and Femoral Neck Fracture Surgery prevention initiative other antimicrobial agent vs. a betalactam without vancomycin Cefazolin and vancomycin vs. vancomycin Hip Teicoplanin and cefuroxime vs cefuroxime CDC definition evaluated for 60 days; did not specify who made CDC definition; assessed by infection control staff CDC definition; did not (0.05, 15.93) 0.48 b (0.05, 4.53) 0.38 b (0.13, 1.07) 0.07 b (0.01, 0.58) a Some studies provided data on only S. aureus SSIs, not all Gram-positive SSIs; b These studies provided data on only S. aureus SSIs not all Gram-positive SSIs te:, methicillin-resistant S. aureus; RCT, randomized controlled trial;, quasi-experimental; RR, relative risk; CI, confidence interval; CDC, Centers for Disease and Prevention; NHSN, National Health Safety Network; VA, Veterans Administration; SSI, surgical site infection
Responders as percent of overall members in each category: Practice: Adult 490 (49% of 1009 members) 57 (54% of 106 members)
Infectious Diseases Society of America Emerging Infections Network 6/2/10 Report for Query: Perioperative Staphylococcus aureus Screening and Decolonization Overall response rate: 674/1339 (50.3%) physicians
More informationPreventing Surgical Site Infections. Edward L. Goodman, MD September 16, 2013
Preventing Surgical Site Infections Edward L. Goodman, MD September 16, 2013 Outline NHSN Reporting and Definitions Magnitude of the Problem Risk Factors Non Pharmacologic Interventions Pharmacologic Interventions
More information2017 SURVEILLANCE OF SURGICAL SITES INFECTIONS FOLLOWING TOTAL HIP AND KNEE ARTHROPLASTY
Canadian Nosocomial Infection Surveillance Program 2017 SURVEILLANCE OF SURGICAL SITES INFECTIONS FOLLOWING TOTAL HIP AND KNEE ARTHROPLASTY FINAL Working Group: E. Henderson, M. John, I. Davis, S. Dunford,
More informationTreatment of Surgical Site Infection Meeting Quality Statement 6. Prof Peter Wilson University College London Hospitals
Treatment of Surgical Site Infection Meeting Quality Statement 6 Prof Peter Wilson University College London Hospitals TEG Quality Standard 6 Treatment and effective antibiotic prescribing: People with
More informationThe role of Infection Control Nurse in Prevention of Surgical Site Infection (SSI) April 2013
The role of Infection Control Nurse in Prevention of Surgical Site Infection (SSI) April 2013 Impact of SSI 2 nd common health- care associated infection (HCAI) 14-16% of HCAI Post operation SSI prolong
More informationCanadian Nosocomial Infection Surveillance Program 2018 SURVEILLANCE OF SURGICAL SITES INFECTIONS FOLLOWING HIP AND KNEE ARTHROPLASTY
Canadian Nosocomial Infection Surveillance Program 2018 SURVEILLANCE OF SURGICAL SITES INFECTIONS FOLLOWING HIP AND KNEE ARTHROPLASTY FINAL Working Group: Dominik Mertz (Chair) Elizabeth Henderson, Johan
More informationORIGINAL INVESTIGATION. Sustained Reduction in Methicillin-Resistant Staphylococcus aureus Wound Infections After Cardiothoracic Surgery. surgery.
ONLINE FIRST ORIGINAL INVESTIGATION Sustained Reduction in Methicillin-Resistant Staphylococcus aureus Wound Infections After Cardiothoracic Surgery Edward E. Walsh, MD; Linda Greene, RN; Ronald Kirshner,
More informationSurveillance cultures: Can they help our decisions
Surveillance cultures: Can they help our decisions Trish M. Perl MD, MSc Professor of Medicine, Pathology and Epidemiology Johns Hopkins School of Medicine and Bloomberg School of Public Health tperl@jhmi.edu
More informationPrevention of Surgical Site Infections
Prevention of Surgical Site Infections A Review of Recent Evidence and Guidelines Dale W. Bratzler, DO, MPH, MACOI, FIDSA Professor and Associate Dean, College of Public Health Professor, College of Medicine
More informationConflict of interest: We have no conflict of interest to report on this topic of SSI reduction for total knees.
Reducing SSI- Knees TIFFANY KENNERK MBA, MSN, RN, NE -BC, ONC CYNTHIA SEAMAN BSN, RN, ONC, CMSRN ~COMMUNITY HOSPITALS AND WELLNESS CENTERS~ Conflict of interest: We have no conflict of interest to report
More informationLearning Objectives:
Preventing Surgical Site Infections (SSI) Learning Objectives: Discuss risk factors for surgical site infections in healthcare settings. Review current strategies and emerging guidelines for SSI prevention.
More informationSurgical prophylaxis for Gram +ve & Gram ve infection
Surgical prophylaxis for Gram +ve & Gram ve infection Professor Mark Wilcox Clinical l Director of Microbiology & Pathology Leeds Teaching Hospitals & University of Leeds, UK Heath Protection Agency Surveillance
More informationSuccess for a MRSA Reduction Program: Role of Surveillance and Testing
Success for a MRSA Reduction Program: Role of Surveillance and Testing Singapore July 13, 2009 Lance R. Peterson, MD Director of Microbiology and Infectious Disease Research Associate Epidemiologist, NorthShore
More informationDoes Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs?
Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs? John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control and
More informationCellulitis. Assoc Prof Mark Thomas. Conference for General Practice Auckland Saturday 28 July 2018
Cellulitis Assoc Prof Mark Thomas Conference for General Practice Auckland Saturday 28 July 2018 Summary Cellulitis Usual treatment flucloxacillin for 5 days Frequent recurrences consider penicillin 250mg
More informationMeasure #21 (NQF 0268): Perioperative Care: Selection of Prophylactic Antibiotic First OR Second Generation Cephalosporin
Measure #21 (NQF 0268): Perioperative Care: Selection of Prophylactic Antibiotic First OR Second Generation Cephalosporin 2013 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION: Percentage
More informationSurgical Site Infection (SSI) Prevention: The Latest, Greatest and Unanswered Questions
Surgical Site Infection (SSI) Prevention: The Latest, Greatest and Unanswered Questions Keith S. Kaye, MD, MPH Corporate Vice President of Quality and Patient Safety Corporate Medical Director, Infection
More informationPerioperative Antibiotics
Perioperative Antibiotics Liaison: Erik Hansen MD Leaders: Katherine Belden MD, Randi Silibovsky MD (US), Markus Vogt MD (International) Delegates: William Arnold MD, PhD, Goran Bicanic MD, PhD, Stefano
More informationProtocol for exit-site care and treatment of exit-site infections in peritoneal dialysis CONTROLLED DOCUMENT
CONTROLLED DOCUMENT Protocol for exit-site care and treatment of exit-site infections in peritoneal dialysis CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Guideline Clinical The purpose
More informationInfection Control Priorities for Antibiotics Resistance - The Search and Destroy Strategy. WH Seto Hong Kong China
Infection Control Priorities for Antibiotics Resistance - The Search and Destroy Strategy WH Seto Hong Kong China WHD 2011 slogan Tier 1 Education Surveillance Environment Administration Usage IC isolation
More informationAntimicrobial prophylaxis. Bs Lưu Hồ Thanh Lâm Bv Nhi Đồng 2
Antimicrobial prophylaxis Bs Lưu Hồ Thanh Lâm Bv Nhi Đồng 2 Definition The United States Centers for Disease Control and Prevention (CDC) has developed criteria that define surgical site infection (SSI)
More informationMRSA What We Need to Know Sharon Pearce, CRNA, MSN Carolina Anesthesia Associates
MRSA What We Need to Know Sharon Pearce, CRNA, MSN Carolina Anesthesia Associates What is MRSA? Methicillin-resistant Staphylococus aureus This hardy bacterium has developed resistance to every antibiotic
More informationTop Ten Articles Infection Prevention and Control
Top Ten Articles Infection Prevention and Control 2017-2018 John M Conly MD Chingiz Amirov Just wash em! May 2018 Objectives Research or evidence-based guidelines in IPC Critique strengths and weaknesses
More informationScottish Surveillance of Healthcare Infection Programme (SSHAIP) Health Protection Scotland SSI Surveillance Protocol 7th Edition 2017 Question &
Contents General... 4 Pre-op... 4 Peri-op... 5 Post-op... 8 Caesarean Section... 12 Orthopaedics... 14 Large Bowel:... 15 Vascular... 17 General Pre-op Q: If a patient is an emergency admission is the
More informationMRSA in the United Kingdom status quo and future developments
MRSA in the United Kingdom status quo and future developments Dietrich Mack Chair of Medical Microbiology and Infectious Diseases The School of Medicine - University of Wales Swansea P R I F Y S G O L
More informationSURGICAL ANTIBIOTIC PROPHYLAXIS GUIDELINES WITHIN ORTHOPAEDIC SURGERY FOR ADULT PATIENTS
SURGICAL ANTIBIOTIC PROPHYLAXIS GUIDELINES WITHIN ORTHOPAEDIC SURGERY FOR ADULT PATIENTS Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if
More informationBeyond SCIP: Leading the Way to SSI Reduction. House Keeping. House Keeping. Questions. Dianne Rawson, RN, MA Hugo, MN May 14, 2013
3M Learning Connection 5/7/2013 3M Infection Prevention Solutions Learning Connection Beyond SCIP: Leading the Way to SSI Reduction Dianne Rawson, RN, MA Hugo, MN May 14, 2013 2012. All Rights Reserved.
More informationApproval Signature: Original signed by Dr. Michel Tetreault Date of Approval: July Review Date: July 2017
WRHA Infection Prevention and Control Program Operational Directives Admission Screening for Antibiotic Resistant Organisms (AROs): Methicillin Resistant Staphylococcus aureus (MRSA) and Vancomycin Resistant
More informationAntibiotic Stewardship at MetroWest Medical Center. Colleen Grocer, RPh, BCOP Co-Chair, Antibiotic Stewardship Committee
Antibiotic Stewardship at MetroWest Medical Center Colleen Grocer, RPh, BCOP Co-Chair, Antibiotic Stewardship Committee Antibiotic Stewardship Committee Subcommittee of Pharmacy and Therapeutics. Also
More informationCLINICAL USE OF BETA-LACTAMS
CLINICAL USE OF BETA-LACTAMS Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu WHY IS INFECTIOUS DISEASE PHARMACOTHERAPY SO CONFUSING? Microbial
More informationDeveloped by Kathy Wonderly RN, MSEd,CPHQ Developed: October 2009 Most recently updated: December 2014
Developed by Kathy Wonderly RN, MSEd,CPHQ Developed: October 2009 Most recently updated: December 2014 The Center for Medicare and Medicaid (CMS) is moving away from collecting data on the process of care
More informationFM - Male, 38YO. MRSA nasal swab (+) Due to positive MRSA nasal swab test, patient will be continued on Vancomycin 1500mg IV q12 for MRSA treatment...
Jillian O Keefe Doctor of Pharmacy Candidate 2016 September 15, 2015 FM - Male, 38YO HPI: Previously healthy male presents to ED febrile (102F) and in moderate distress ~2 weeks after getting a tattoo
More informationWHO Surgical Site Infection Prevention Guidelines. Web Appendix 4
WHO Surgical Site Infection Prevention Guidelines Web Appendix 4 Summary of a systematic review on screening for extended spectrum betalactamase and the impact on surgical antibiotic prophylaxis 1. Introduction
More informationPost-operative surgical wound infection
Med. J. Malaysia Vol. 45 No. 4 December 1990 Post-operative surgical wound infection Yasmin Abu Hanifah, MBBS, MSc. (London) Lecturer Department of Medical Microbiology, Faculty of Medicine, University
More informationMeasure #20 (NQF 0270): Perioperative Care: Timing of Prophylactic Parenteral Antibiotic Ordering Physician
Measure #20 (NQF 0270): Perioperative Care: Timing of Prophylactic Parenteral Antibiotic Ordering Physician 2014 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION: Percentage of surgical
More informationEvaluating the Role of MRSA Nasal Swabs
Evaluating the Role of MRSA Nasal Swabs Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds February 28, 2017 2016 MFMER slide-1 Objectives Identify the pathophysiology of MRSA nasal colonization
More informationOptimizing Antibiotic Treatment of Skin and Soft Tissue Infections
Optimizing Antibiotic Treatment of Skin and Soft Tissue Infections 15th Annual Rocky Mountain Hospital Medicine Symposium November 6, 2017 Tim Jenkins, MD Director, Antibiotic Stewardship Program Denver
More informationGive the Right Antibiotics in Trauma Mitchell J Daley, PharmD, BCPS
Give the Right Antibiotics in Trauma Mitchell J Daley, PharmD, BCPS Clinical Pharmacy Specialist, Critical Care Dell Seton Medical Center at the University of Texas and Seton Healthcare Family Clinical
More informationCanadian Nosocomial Infection Surveillance Program 2018 SURVEILLANCE FOR HEALTHCARE ACQUIRED CEREBROSPINAL FLUID SHUNT ASSOCIATED INFECTIONS
Canadian Nosocomial Infection Surveillance Program 2018 SURVEILLANCE FOR HEALTHCARE ACQUIRED CEREBROSPINAL FLUID SHUNT ASSOCIATED INFECTIONS FINAL November 29, 2017 Working Group: Joanne Langley (Chair),
More informationAppropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases
Appropriate Management of Common Pediatric Infections Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases It s all about the microorganism The common pathogens Viruses
More informationAn Evidence Based Approach to Antibiotic Prophylaxis in Oral Surgery
An Evidence Based Approach to Antibiotic Prophylaxis in Oral Surgery Nicholas Makhoul DMD. MD. FRCD(C). Dip ABOMS. FACS. Director, Division of Oral and Maxillofacial Surgery Assistant Professor McGill
More informationPromoting Appropriate Antimicrobial Prescribing in Secondary Care
Promoting Appropriate Antimicrobial Prescribing in Secondary Care Stuart Brown Healthcare Acquired Infection and Antimicrobial Resistance Project Lead NHS England March 2015 Introduction Background ESPAUR
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationLe infezioni di cute e tessuti molli
Le infezioni di cute e tessuti molli SCELTE e STRATEGIE TERAPEUTICHE Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Treatment of complicated skin and skin structure infections
More informationDevelopment of Drugs for Eradication of Nasal Carriage of S. aureus to Reduce S. aureus Infections in Vulnerable Surgical Patients
Development of Drugs for Eradication of Nasal Carriage of S. aureus to Reduce S. aureus Infections in Vulnerable Surgical Patients Richard Bax Transcrip Partners Bax - Eradication of carriage - EMA 25-26
More informationCa-MRSA Update- Hand Infections. Washington Hand Society September 19, 2007
Ca-MRSA Update- Hand Infections Washington Hand Society September 19, 2007 Resistant Staph. Aureus Late 1940 s -50% S.Aureus resistant to PCN 1957-80/81 strain- of S.A. highly virulent and easily transmissible
More informationComparison of Gentamicin and Mupirocin in the Prevention of Exit-Site Infection and Peritonitis in Peritoneal Dialysis
Advances in Peritoneal Dialysis, Vol. 25, 2009 Anshinee Mahaldar, Michael Weisz, Pranay Kathuria Comparison of Gentamicin and Mupirocin in the Prevention of Exit-Site Infection and Peritonitis in Peritoneal
More informationBoard Meeting Agenda Item: 7.2 Paper No: Purpose: For Information. Healthcare Associated Infection Report
Board Meeting 9.. Agenda Item: 7. Paper No: 6- Purpose: For Information Healthcare Associated Infection Report August/September Board Meeting 9.. Agenda Item: 7. Paper No: 6- Purpose: For Information August/September
More informationDiabetic Foot Infection. Dr David Orr Consultant Microbiologist Lancashire Teaching Hospitals
Diabetic Foot Infection Dr David Orr Consultant Microbiologist Lancashire Teaching Hospitals History of previous amputation [odds ratio (OR)=19.9, P=.01], Peripheral vascular disease (OR=5.5, P=.007)
More informationProc. related Joseph Lister - antiseptic principles Zoutman et al Inf Contr Hosp Epi 1999
Dick Zoutman, MD, FRCPC Queen s University School of Medicine & Kingston General Hospital, Kingston, Ontario, Canada Hosted by Paul Webber paul@webbertraining.com www.webbertraining.com Practical Meaning
More informationHealthcare-associated Infections Annual Report December 2018
December 2018 Healthcare-associated Infections Annual Report 2011-2017 TABLE OF CONTENTS INTRODUCTION... 1 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS... 2 MRSA SURVEILLANCE... 3 CLOSTRIDIUM
More informationThe surgical site infection risk in developing countries. Yves BUISSON Société de Pathologie Exotique
The surgical site infection risk in developing countries Yves BUISSON Société de Pathologie Exotique Surgical site infections Health-care-associated infections occurring within 30 days after surgery, or
More informationMethicillin-Resistant Staphylococcus aureus (MRSA) Infections Activity C: ELC Prevention Collaboratives
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Activity C: ELC Prevention Collaboratives John Jernigan, MD, MS Alex Kallen, MD, MPH Division of Healthcare Quality Promotion Centers for Disease
More informationInfection control in intensive care. Sandra Fairley Senior Nurse, Neurocritical Care
Infection control in intensive care Sandra Fairley Senior Nurse, Neurocritical Care sandra.fairley@uclh.nhs.uk Risks to the patient of health care acquired infection (HCAI) Patient admitted to hospital
More informationNeurosurgery Antibiotic Prophylaxis Guideline
Neurosurgery Antibiotic Prophylaxis Guideline Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review date (when this version
More informationReplaces:04/14/16. Formulated: 1997 SKIN AND SOFT TISSUE INFECTION
Effective Date: 04/13/17 Replaces:04/14/16 Page 1 of 7 POLICY To standardize the clinical management and housing of offenders with skin and soft tissue infections, thereby reducing the transmission and
More informationWhat s New in MRSA? An Update on Legislative Mandates and MRSA in the Obstetrics/ Gynecology Patient
What s New in MRSA? An Update on Legislative Mandates and MRSA in the Obstetrics/ Gynecology Patient Catherine Liu, M.D. Assistant Clinical Professor University of California, San Francisco Overview New
More informationAntimicrobial Susceptibility Patterns
Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department
More informationComplications in Pelvic Floor Surgery: Peri operative infective complications
IUGA W19: 4 September 2012 Workshop notes Complications in Pelvic Floor Surgery: Peri operative infective complications A/Professor Mary O Reilly MBBS FRACP MPH Eastern Health; Faculty of Medicine, Nursing
More informationAntibiotic Abyss. Discussion Points. MRSA Treatment Guidelines
Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California
More informationHyperlink to Guideline
Clinical Guideline Surgical Antibiotic Prophylaxis Sites where Clinical Guideline applies All facilities where surgery is carried out This Clinical Guideline applies to: 1. Adults Yes 2. Children up to
More informationPerichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV
Empiric Antibiotics for Pediatric Infections Seen in ED NOTE: Choice of empiric antibiotic therapy must take into account local pathogen frequency and resistance patterns, individual patient characteristics,
More informationProphylactic antibiotics for insertion of peritoneal dialysis catheter
Prophylactic antibiotics for insertion of peritoneal dialysis catheter Date written: October 2010 Final submission: September 2012 Author: Maha Yehia GUIDELINES a. Intravenous antibiotic prophylaxis should
More informationNorth West Neonatal Operational Delivery Network Working together to provide the highest standard of care for babies and families
Document Title and Reference : Guideline for the management of multi-drug resistant organisms (MDRO) Main Author (s) Simon Power Ratified by: GM NSG Date Ratified: February 2012 Review Date: March 2017
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationPVL Staph aureusjust a skin/soft tissue problem? Layla Mohammadi Lead Pharmacist, Antimicrobials Lewisham Healthcare NHS Trust
PVL Staph aureusjust a skin/soft tissue problem? Layla Mohammadi Lead Pharmacist, Antimicrobials Lewisham Healthcare NHS Trust Neonatal Case History Neonate born at 26 +2 gestation Spontaneous onset of
More informationReducing Infections in Surgical Practice. Fred A Sweet, MD Rockford Spine Center Illinois, USA
Reducing Infections in Surgical Practice Fred A Sweet, MD Rockford Spine Center Illinois, USA Introduction: How bacteria get in The Host The Surgeon The Procedure The STAFF Skin PREP Prophylactic Antibiotics
More informationLA-MRSA in the Netherlands: the past, presence and future.
LA-MRSA in the Netherlands: the past, presence and future. Prof. Jaap Wagenaar DVM, PhD With input from Prof. Jan Kluytmans MD, PhD Department of Infectious Diseases and Immunology, Faculty of Veterinary
More informationGeneral Approach to Infectious Diseases
General Approach to Infectious Diseases 2 The pharmacotherapy of infectious diseases is unique. To treat most diseases with drugs, we give drugs that have some desired pharmacologic action at some receptor
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. 8. Prophylactic antibiotics for insertion of peritoneal dialysis catheter
8. Prophylactic antibiotics for insertion of peritoneal dialysis catheter Date written: February 2003 Final submission: May 2004 Guidelines (Include recommendations based on level I or II evidence) Antibiotic
More informationProphylactic antibiotic timing and dosage. Dr. Sanjeev Singh AIMS, Kochi
Prophylactic antibiotic timing and dosage Dr. Sanjeev Singh AIMS, Kochi Meaning - Webster Medical Definition of prophylaxis plural pro phy lax es \-ˈlak-ˌsēz\play : measures designed to preserve health
More informationPocket Guide to Diagnosis & Treatment of Cardiovascular Implantable Electronic Device (CIED) Infections
Pocket Guide to Diagsis & Treatment of Cardiovascular Implantable Electronic Device (CIED) Infections Draft Version : November 208 DEFINITION Pocket infection, if all 4 criteria are fulfilled: Investigation/sign
More informationCLPNA Pressure Ulcers ecourse: Module 5.6 Quiz II page 1
CLPNA Pressure Ulcers ecourse: Module 5.6 Quiz II 1. What are the symptoms of an infected wound? a. Fever b. Edema c. Erythema d. Local pain and tenderness e. Induration of wound edge 2. A person with
More informationInfection Prevention Highlights for the Medical Staff. Pamela Rohrbach MSN, RN, CIC Director of Infection Prevention
Highlights for the Medical Staff Pamela Rohrbach MSN, RN, CIC Director of Infection Prevention Standard Precautions every patient every time a. Hand Hygiene b. Use of Personal Protective Equipment (PPE)
More informationVCH PHC SURGICAL PROPHYLAXIS RECOMMENDATIONS
VCH PHC SURGICAL PROPHYLAXIS RECOMMENDATIONS CARDIAC Staphylococcus aureus, S. epidermidis, except for For patients with known MRSA colonization, recommend decolonization with Antimicrobial Photodynamic
More informationAntibiotic Prophylaxis Update
Antibiotic Prophylaxis Update Choosing Surgical Antimicrobial Prophylaxis Peri-Procedural Administration Surgical Prophylaxis and AMS at Epworth HealthCare Mr Glenn Valoppi Dr Trisha Peel Dr Joseph Doyle
More informationAntimicrobial Stewardship Programs The Same, but Different. Sara Nausheen, MD Kevin Kern, PharmD
Antimicrobial Stewardship Programs The Same, but Different Sara Nausheen, MD Kevin Kern, PharmD Antimicrobial Stewardship Programs The Same, but Different Objectives: Outline the overall function of an
More informationFelipe N. Gutierrez MD, MPH Chief, Infectious Diseases Phoenix VA Healthcare
Felipe N. Gutierrez MD, MPH Chief, Infectious Diseases Phoenix VA Healthcare 100% of all wounds will yield growth If you get a negative culture you something is wrong! Pseudomonas while ubiquitous does
More informationScreening programmes for Hospital Acquired Infections
Screening programmes for Hospital Acquired Infections European Diagnostic Manufacturers Association In Vitro Diagnostics Making a real difference in health & life quality June 2007 HAI Facts Every year,
More informationRecommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland
Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland A report by the Hospital Antimicrobial Stewardship Working Group, a subgroup of the
More informationMeasure Information Form
Release Notes: Measure Information Form Version 2.0 **NQF-NDORSD VOLUNTRY CONSNSUS STNDRDS FOR HOSPITL CR** Measure Information Form Measure Set: Surgical Care Improvement Project (SCIP) Set Measure ID
More informationPresenter: Marc Meyer, BPharm, RPh, CIC, FAPIC Clinical Pharmacists, Infection Preventionist, Antibiotic Stewardship Pharmacist Southwest Health
Presenter: Marc Meyer, BPharm, RPh, CIC, FAPIC Clinical Pharmacists, Infection Preventionist, Antibiotic Stewardship Pharmacist Southwest Health System, Cortez, Colorado None How do AU vendors and NHSN
More information1) Mangram AJ,Horan TC,Pearson ML, et al:guideline for Prevention of Surgical Site Infection.Infect Control Hosp Epidemiol 1999;20:247-278. 1a) Perl TM, Cullen JJ, Wenzel RP, et al.: Intranasal mupirocin
More informationMulti-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED Printed copies must not be considered the definitive version
Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED 2018 Printed copies must not be considered the definitive version DOCUMENT CONTROL POLICY NO. IC-122 Policy Group Infection Control
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationConsumption of antibiotics in hospitals. Antimicrobial stewardship.
Consumption of antibiotics in hospitals. Antimicrobial stewardship. Inge C. Gyssens MD PhD Radboud university medical center, Nijmegen, The Netherlands Hasselt University, Belgium 1. Antibiotic use in
More informationWho should read this document? 2. Key practice points 2. Background/ Scope/ Definitions 2. What is new in this version? 3
Neurosurgical infections (adult only) Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): as above Authors Division: DCSS & Tertiary
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationMRSA Outbreak in Firefighters
MRSA Outbreak in Firefighters Angie Carranza Munger, MD Resident, Occupational and Environmental Medicine The University of Colorado, Denver and National Jewish Health Candidate, Masters of Public Health
More informationOptimal Use Report CADTH. Canadian Agency for Drugs and Technologies in Health. Agence canadienne des médicaments et des technologies de la santé
Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé Optimal Use Report CADTH Volume 2, Issue 2A April 2012 Screening, Isolation, and Decolonization
More informationPreventing Multi-Drug Resistant Organism (MDRO) Infections. For National Patient Safety Goal
Preventing Multi-Drug Resistant Organism (MDRO) Infections For National Patient Safety Goal 07.03.01 2009 Methicillin Resistant Staphlococcus aureus (MRSA) About 3-8% of the population at large is a carrier
More informationActive Bacterial Core Surveillance Site and Epidemiologic Classification, United States, 2005a. Copyright restrictions may apply.
Impact of routine surgical ward and intensive care unit admission surveillance cultures on hospital-wide nosocomial methicillin-resistant Staphylococcus aureus infections in a university hospital: an interrupted
More informationRisk factors? Insect bites? Hygiene? Household crowding Health literacy
Recurrent boils Commonest sites face, neck, armpits, shoulders, and buttocks (bottom) infection of the hair root or sweat pore Occur in otherwise healthy people (higher rates in diabetics, eczema, iron
More informationAntimicrobial utilization: Capital Health Region, Alberta
ANTIMICROBIAL STEWARDSHIP Antimicrobial utilization: Capital Health Region, Alberta Regionalization of health care services in Alberta began in 1994. In the Capital Health region, restructuring of seven
More informationHorizontal vs Vertical Infection Control Strategies
GUIDE TO INFECTION CONTROL IN THE HOSPITAL Chapter 14 Horizontal vs Vertical Infection Control Strategies Author Salma Abbas, MBBS Michael Stevens, MD, MPH Chapter Editor Shaheen Mehtar, MBBS. FRC Path,
More information8/17/2016 ABOUT US REDUCTION OF CLOSTRIDIUM DIFFICILE THROUGH THE USE OF AN ANTIMICROBIAL STEWARDSHIP PROGRAM
Mary Moore, MS CIC MT (ASCP) Infection Prevention Coordinator Great River Medical Center, West Burlington REDUCTION OF CLOSTRIDIUM DIFFICILE THROUGH THE USE OF AN ANTIMICROBIAL STEWARDSHIP PROGRAM ABOUT
More informationMODELING THE EPIDEMIOLOGIC AND ECONOMIC IMPACTS OF NOSOCOMIAL INFECTION PREVENTION STRATEGIES. Rachel Rubin Bailey. B.S., Tulane University, 2007
MODELING THE EPIDEMIOLOGIC AND ECONOMIC IMPACTS OF NOSOCOMIAL INFECTION PREVENTION STRATEGIES by Rachel Rubin Bailey B.S., Tulane University, 2007 M.P.H., University of Pittsburgh, 2008 Submitted to the
More informationTrust Guideline for the Management of: Antibiotic Prophylaxis in adults undergoing procedures in Interventional Radiology
Antibiotic Prophylaxis in adults undergoing procedures in Interventional Radiology A Clinical Guideline For use in: By: For: Division responsible for document: Key words: Interventional Radiology Prescribers
More informationLINEE GUIDA: VALORI E LIMITI
Ferrara 28 novembre 2014 LINEE GUIDA: VALORI E LIMITI Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi EVIDENCE BIASED GERIATRIC MEDICINE Older patients with comorbid conditions
More informationAntibiotic Prophylaxis in Spinal Surgery Antibiotic Guidelines. Contents
Antibiotic Prophylaxis in Spinal Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): Authors Division: DCSS & Tertiary Medicine Unique
More information